Published in J Clin Endocrinol Metab on September 01, 1986
Motivations and methods for analyzing pulsatile hormone secretion. Endocr Rev (2008) 2.01
The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci U S A (2007) 1.37
TSH and Thyrotropic Agonists: Key Actors in Thyroid Homeostasis. J Thyroid Res (2012) 0.96
Homeostatic Control of the Thyroid-Pituitary Axis: Perspectives for Diagnosis and Treatment. Front Endocrinol (Lausanne) (2015) 0.80
The Colorado thyroid disease prevalence study. Arch Intern Med (2000) 7.84
Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med (2000) 2.80
Eating disorders. N Engl J Med (1999) 2.77
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70
Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med (2001) 2.57
Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab (1996) 2.37
A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab (2010) 2.33
Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab (1996) 2.30
Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology (1996) 2.28
Determinants of increased energy expenditure in HIV-infected women. Am J Clin Nutr (1998) 2.21
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 2.16
Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss. Am J Transplant (2014) 2.09
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 2.08
Brain: gadolinium-enhanced fast fluid-attenuated inversion-recovery MR imaging. Radiology (1999) 2.07
Androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab (2001) 1.95
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab (1999) 1.92
Changes in regional fat redistribution and the effects of estrogen during spontaneous weight gain in women with anorexia nervosa. Am J Clin Nutr (2001) 1.91
Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab (1998) 1.91
The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab (1999) 1.89
L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann Intern Med (1984) 1.88
A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. J Clin Endocrinol Metab (1996) 1.85
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Thyroid hormone regulates the mouse thyrotropin beta-subunit gene promoter in transfected primary thyrotropes. J Biol Chem (1989) 1.84
Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab (1997) 1.76
Do traditional symptoms of hypothyroidism correlate with biochemical disease? J Gen Intern Med (1997) 1.75
Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med (2000) 1.74
A clinical trial of creatine in ALS. Neurology (2004) 1.73
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology (2006) 1.73
Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab (2001) 1.72
The influence of gonadal hormones on conditioned fear extinction in healthy humans. Neuroscience (2010) 1.69
Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab (1998) 1.68
Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol (1993) 1.67
Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J Clin Endocrinol Metab (1989) 1.61
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
Osteopenia in men with a history of delayed puberty. N Engl J Med (1992) 1.59
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab (2000) 1.58
Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab (1998) 1.57
Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement. N Engl J Med (1977) 1.55
Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab (1996) 1.54
Thyroid hormone resistance syndromes. Am J Med (1993) 1.54
Decreased bone density in hyperprolactinemic women. N Engl J Med (1980) 1.53
'Senile' osteoporosis reconsidered. JAMA (1989) 1.51
Statistical considerations for pilot studies. Int J Radiat Oncol Biol Phys (1980) 1.50
Assessment of macronutrient and micronutrient intake in women with anorexia nervosa. Int J Eat Disord (2000) 1.49
Body fat distribution measured with CT: correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome. Radiology (1989) 1.46
Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int (2000) 1.45
Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates. Am J Transplant (2014) 1.44
Hypothyroidism-induced macroorchidism: use of a gonadotropin-releasing hormone agonist to understand its mechanism and augment adult stature. J Clin Endocrinol Metab (1995) 1.43
Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab (2001) 1.42
Secondary malignancy of the thyroid gland: a case report and review of the literature. Thyroid (1994) 1.41
Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab (2003) 1.38
Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab (1997) 1.36
Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med (1994) 1.36
Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med (1987) 1.34
Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med (1996) 1.34
Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab (1992) 1.34
Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med (1986) 1.34
Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med (2000) 1.33
Transcriptional regulation of the thyrotropin subunit genes by thyroid hormone. J Biol Chem (1985) 1.33
Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J Clin Endocrinol Metab (2004) 1.31
Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea. J Clin Endocrinol Metab (1999) 1.31
Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA (1998) 1.30
Global self-ratings of health and mortality: hazard in the North Carolina Piedmont. J Clin Epidemiol (1996) 1.30
Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med (1983) 1.29
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int (2014) 1.29
Suppression of pituitary TSH secretion in the patient with a hyperfunctioning thyroid nodule. J Clin Invest (1973) 1.27
Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab (2006) 1.27
Pituitary-specific Gata2 knockout: effects on gonadotrope and thyrotrope function. Mol Endocrinol (2006) 1.27
Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest (1990) 1.27
A consensus on the diagnosis and treatment of acromegaly complications. Pituitary (2013) 1.26
Effects of fasting and glucose infusion on basal and overnight leptin concentrations in normal-weight women. Am J Clin Nutr (1997) 1.26
Serum leptin levels in women with anorexia nervosa. J Clin Endocrinol Metab (1996) 1.26
Spectrum of pituitary alterations with mild and severe thyroid impairment. J Clin Endocrinol Metab (1978) 1.24
Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med (1987) 1.23
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res (2002) 1.22
Free alpha-subunit is superior to luteinizing hormone as a marker of gonadotropin-releasing hormone despite desensitization at fast pulse frequencies. J Clin Endocrinol Metab (1999) 1.22
Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2006) 1.21
Enhancer-mediated high level expression of mouse pituitary glycoprotein hormone alpha-subunit transgene in thyrotropes, gonadotropes, and developing pituitary gland. Mol Endocrinol (1994) 1.20
Substrate cycling between gluconeogenesis and glycolysis in euthyroid, hypothyroid, and hyperthyroid man. J Clin Invest (1985) 1.20
Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab (2001) 1.20
Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int (2010) 1.19
Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int (1994) 1.18
Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab (1989) 1.18
Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab (2000) 1.17
Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. Circulation (2001) 1.17
The use of statistical MUNE in a multicenter clinical trial. Muscle Nerve (2004) 1.17
Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis (2000) 1.16
The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. J Clin Endocrinol Metab (1976) 1.15
Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab (1996) 1.15
Neuroendocrine-gonadal axis in men: frequent sampling of LH, FSH, and testosterone. Am J Physiol (1988) 1.15
Functional outcome measures as clinical trial endpoints in ALS. Neurology (2004) 1.15